Shares of Celyad SA (NASDAQ:CYAD) have earned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.
Brokerages have set a 12 month consensus price target of $35.67 for the company, according to Zacks. Zacks has also given Celyad SA an industry rank of 160 out of 265 based on the ratings given to its competitors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2017/06/20/celyad-sa-cyad-given-consensus-rating-of-buy-by-brokerages-updated-updated-updated-updated.html.
An institutional investor recently raised its position in Celyad SA stock. Victory Capital Management Inc. boosted its position in Celyad SA (NASDAQ:CYAD) by 6.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 374,493 shares of the company’s stock after buying an additional 22,600 shares during the period. Victory Capital Management Inc. owned 3.93% of Celyad SA worth $9,988,000 as of its most recent SEC filing. Institutional investors own 4.95% of the company’s stock.
Shares of Celyad SA (NASDAQ:CYAD) traded up 2.66% during mid-day trading on Tuesday, hitting $40.58. The stock had a trading volume of 786 shares. The stock’s market capitalization is $386.32 million. The stock has a 50 day moving average of $33.69 and a 200-day moving average of $23.72. Celyad SA has a 52 week low of $16.31 and a 52 week high of $59.50.
Celyad SA Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.